A Randomized Prospective Study of Cefepime Plus Metronidazole with Imipenem-Cilastatin in the Treatment of Intra-abdominal Infections by Garbino, J. et al.
Infection 35 · 2007 · No. 3 © URBAN & VOGEL 161
Infection Clinical and Epidemiological Study
A Randomized Prospective Study of Cefepime Plus 
Metronidazole with Imipenem-Cilastatin in the 
Treatment of Intra-abdominal Infections
J. Garbino, P. Villiger, A. Caviezel, R. Matulionyte, I. Uckay, P. Morel, D. Lew
Abstract
Background: Presumptive antimicrobial therapy is an 
important aspect of the management of intra-abdominal 
infections. Together with surgery, antimicrobial combinations 
are still widely used to achieve the required spectrum of 
activity. The aim of this study was to evaluate the efficacy 
of parenteral cefepime + metronidazole vs imipenem-
cilastatin for the treatment of intra-abdominal infections in 
adult patients.
Methods: Patients with a clinically confirmed diagnosis of 
intra-abdominal infection were randomized to one of two 
treatment regimens: cefepime 2 g iv/12 h plus metroni-
dazole 500 mg/8 h or imipenem-cilastatin 500 mg iv/6 h. 
The primary measure of clinical response was the decline 
of pre-treatment signs and symptoms of infection. The 
duration of follow-up was 30 days. Treatment failure was 
defined as either a lack of improvement or a worsening of 
pre-treatment signs and symptoms of infection. Surgical 
management of the infection was determined by the 
surgeon-in-charge.
Results: Of the 122 intended-to-treat patients included 
in the study, 60 patients (33 men) were randomized to 
cefepime + metronidazole and 61 (27 men) to imipenem-
cilastatin. Cefepime + metronidazole treatment was 
successful in 52 (87%) patients and imipenem-cilastatin in 
44 (72%) patients (p = 0.004). Microbiological eradication 
was established in similar proportions in both groups 
(cefepime + metronidazole, 43; imipenem-cilastatin, 38).
Conclusion: Further studies are warranted to confirm the 
better results with the cefepime + metronidazole regimen for 
the treatment of intra-abdominal infections.
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Background
Presumptive antimicrobial therapy is an important aspect 
of the management of intra-abdominal infections, together 
with surgery and supportive care. Antimicrobial regimens 
must be active against Enterobacteriaceae and anaerobes 
(particularly Bacteroides fragilis) [1]. While the presence 
of enterococci may increase the rate of infectious post-
operative complications or treatment failure [2], it has 
been shown that polymicrobial intra-abdominal infections 
involving Enterococci can be successfully treated with sur-
gical drainage and antibiotics that are not active against 
enterococci [3].
Antimicrobial combinations are still widely used to 
achieve the required spectrum of activity. Formerly, a 
combination of clindamycin or metronidazole with an 
aminoglycoside was considered as a standard therapy for 
peritonitis [4–6]. However, aminoglyosides are associated with 
a risk of nephrotoxicity and ototoxicity [7] and, furthermore, 
resistance of B. fragilis to clindamycin has been ob-
served. The availability of carbapenem, broad-spectrum 
cephalosporins, or fluoroquinolones, with the addition of 
metronidazole when necessary, has led to the replacement of 
aminoglycosides, thus resulting in less potential toxicity.
In several trials in patients with peritonitis, carbap-
enem monotherapy has been reported to be as effective 
as standard combinations in this setting [8–11]. Solomkin 
et al. [12] reported that imipenem-cilastatin was shown to 
be even more effective than a combination of clindamy-
cin and tobramycin in patients with secondary peritonitis. 
Imipenem-cilastatin has been suggested as the treatment 
of choice for peritonitis with clinical efficacy rates close to 
83% [12–14]. The combination of a broad-spectrum cepha-
losporin plus an anti-anaerobic agent has been shown to 
be an alternative to imipenem-cilastatin in the treatment 
of severe intra-abdominal infections in different pub-
lished series. In the study by Berne et al. [15], cefepime + 
metronidazole was compared to clindamycin-gentamicin 
in the treatment of patients with peritonitis. Clinical and 
bacteriological cure rates were higher for the cefepime + 
metronidazole arm (94%/97%) than for the clindamycin-
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gentamicin arm (77%/88%); satisfactory clinical response 
rates were 94% and 77%, respectively [15]. A study of 
the treatment of biliary tract infections requiring surgery 
showed a satisfactory clinical response rate of 97% in the 
cefepime + metronidazole arm vs 92% in the gentami-
cin + mezlocillin arm. Bacteriological eradication rates 
were 97% and 92%, respectively [16]. Another study of 
complicated intra-abdominal infections which compared 
cefepime + metronidazole with imipenem-cilastatin showed 
that 88% of patients treated with cefepime + metronidazole 
were deemed clinically cured vs 76% (p = 0.02) of those 
treated with imipenem-cilastatin [17]. A study with a new 
carbapenem, ertapenem, compared with a combination of 
ceftriaxone + metronizadole demonstrated also an equivalent 
efficacy in the treatment of intra-abdominal infections [18].
This study was conducted to compare the efficacy and 
safety of cefepime + metronidazole with imipenem-cilas-
tatin for the treatment of patients with intra-abdominal 
infections and to confirm if the conclusions of the study 
conducted by Barie et al. [17] were still applicable.
Methods
This prospective, randomized, comparative, clinical trial in adult 
patients with intra-abdominal infections was conducted in a ter-
tiary care university hospital. The study protocol was reviewed 
and approved by the institutional review committee prior to 
implementation. All patients provided written informed consent 
prior to receiving the first dose of the study drug.
Eligible patients were allocated to one of the two regimens 
according to a random computer-generated list using a random 
block size of six, which allowed equal numbers of patients in each 
treatment arm. The antibiotic treatment was initiated after the 
double-blinded randomization envelope had been opened by an 
independent study collaborator.
Patients received either cefepime (Maxipime®, Bristol-My-
ers Squibb, Baar, Switzerland) administered intravenously at 
a dose of 2 g twice daily over a period of 30 min plus metroni-
dazole (Flagyl®, Aventis-Pharma, Zurich, Switzerland) adminis-
tered separately at a dose of 500 mg intravenously every 8 h, or 
imipenem-cilastatin (Tienam®, Merck Sharp Dohme-Chibret, 
Glattbrugg, Switzerland) administered at a dose of 500 mg/500 mg 
intravenously every 6 h over a period of 30 min. All drugs were 
dose-adjusted for patients with impaired renal function.
The minimal duration of treatment with the study drug was 
5 days (10 doses of cefepime + metronidazole or 20 doses of imi-
penem–cilastatin for patients whose dosage had not been adjusted 
for renal impairment). The recommended duration of therapy was 
between 7 and 15 days and depended upon the physician’s assess-
ment of the severity of infection and the clinical response. The 
duration of follow-up of all patients was 30 days.
Adult patients (≥ 18 years of age) presenting with a clinically 
diagnosed intra-abdominal infection were eligible for enrolment. 
The diagnosis was confirmed by surgery and in the cases where 
surgery was not performed, a computed tomography (CT) scan 
was performed to confirm the diagnosis (e.g. diverticulitis). Pa-
tients with sigmoid diverticulitis presented the following signs 
and symptoms: muscle guarding; rebound tenderness localized to 
the left iliac fossa or left flank, white blood cells > 10 g/l or white 
blood cells < 4 g/l; and fever ≥ 38 °C. The diagnosis of intra-ab-
dominal infection involved all patients with localized or general-
ized peritonitis. Randomization was performed intra-operatively 
after confirmation of a diagnosis of peritonitis by the surgeon and 
specimens obtained for bacteriological cultures during the surgi-
cal procedure. In some situations where surgical intervention had 
to be deferred for more than 1 h, some patients were randomized 
pre-operatively if presenting with clinical signs and symptoms of 
peritonitis.
Exclusion criteria were pregnant or lactating women; expected 
survival of less than 48 h; known allergy to study drugs; positive 
HIV test; concomitant infection other than intra-abdominal; infec-
tion with microorganisms known to be resistant to the study drugs; 
patients already treated with an antibiotic dose for more than 24 h 
for the same condition within 7 days prior to study entry; and se-
rum transaminases, alkaline phosphatase and bilirubin greater 
than or equal to three times the upper normal limit. The use of 
concomitant systemic antimicrobials in addition to the study drugs 
was not permitted.
Clinical and Bacteriological Assessment
Clinical response at the test-of-cure visit was defined as cured 
when local and systemic clinical signs and symptoms of infection 
that were present during the treatment period had resolved or 
sufficiently improved so that no additional surgical procedures 
or additional or alternative antimicrobial therapy were required. 
Non-responders were defined as patients who fulfilled the follow-
ing conditions: relapse or failure to respond.
Failure occurred under any of the following conditions: insuf-
ficient resolution of a majority of clinical signs and symptoms of 
acute infection; worsening of one or more clinical signs and symp-
toms of infection; requiring alternative antimicrobial therapy or an 
additional surgical procedure. Treatment response was assessed 
by an independent surgeon and infectious diseases specialist.
Bacteriological response was based on the results of the 
appropriate cultures when available. At the test-of-cure visit, bac-
teriological outcomes were categorized as eradication: absence of 
baseline pathogen on culture; presumed eradication: absence of 
evaluable culture in a patient with clinical cure (absence of signs 
and symptoms of infection); failure: presence of baseline pathogen 
in a patient with no clinical response.
All cultures were from intra-abdominal samples. Conventional 
bacteriological cultures were performed according to recom-
mended procedures [19] and the antimicrobial susceptibility of 
bacteria was determined according to the most recently available 
National Committee for Clinical Laboratory Standards (NCCLS) 
[20].
Time of eradication was considered after the patient had re-
ceived at least 5 days of study treatment. Then, the physician 
considered that the patient was cured in the absence of signs and 
symptoms of infection and if cultures were available and showed 
the absence of pathogens.
Safety and Tolerability
Patients were evaluated by physical examination and standard 
serial renal, hepatic, and hematologic laboratory tests. Adverse 
events occurring during post-therapy and serious adverse events 
and deaths (30 days) occurring before the test-of-cure visit period 
were recorded. Adverse event relationship to the study drug was 
categorized by the investigator and ranked as “probable”, “pos-
sible”, “unlikely”, or “none”. Serious adverse events included a 
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life-threatening situation, death, a temporary or permanent dis-
ability, or a need for prolonged hospitalization.
Statistical Methods
All statistical analyses were done using SPSS v11.5 (SPSS Inc., 
Chicago). All tests were based on a significance level of α = 0.05. 
For continuous variables, the independent sample t-test was used 
where the statistical assumptions for such tests were not violated. 
Otherwise, the non-parametric Mann-Whitney tests were applied. 
For the categorical variables, Fisher’s exact test was used.
The primary efficacy analysis (clinical and bacterial responses) 
at test-of-cure was based on a non-inferiority test [21] with the 
non-inferiority margin delta set to δ = 0.1 (10%). If for the non-
inferiority test the null hypothesis (H0: A – B ≤ –δ) was rejected, 
a step-down superiority test for the null hypothesis, H0: A – B = 0, 
was subsequently added. A logistic regression model was used to 
investigate the association of prognostic factors with the likeli-
hood of response. A stepwise forward selection method was ap-
plied to retain the most contributing prognostic factors using as 
selection criteria at p < 0.05.
Results
A total of 122 patients were enrolled in the study with 
61 allocated to each treatment arm; one patient in the 
cefepime + metronidazole arm was excluded due to a pro-
tocol violation. The intention-to-treat (ITT) population 
consisted of 60 patients in the cefepime + metronidazole 
group and 61 patients in the imipenem-cilastatin group.
Treatment groups were comparable with respect to 
age distribution, gender and comorbidities (Table 1). All 
patients presented with abdominal pain and tenderness at 
study entry, and the majority also had abdominal guard-
ing and nausea. An inflammatory process was present in 
all patients in each group consisting primarily of bowel 
perforation, appendicitis, inflammatory bowel disease, co-
lonic-diverticulitis, or ulcer disease. The distribution of all 
surgical infections (infections requiring surgery in addition 
to the antibiotic treatment, n = 84) and no surgical infec-
tions (without surgical procedure, n = 37) were similar in 
both study groups.
Vital signs, mean APACHE II score, hematology and 
serum chemistries at study entry and pre-treatment were 
comparable between the two groups. In each group, 63% 
of the patients received a single pre-operative dose within 
24 h prior to study entry. Sixty-nine percent of the micro-
bial isolates were aerobic organisms and 54% were gram 
negative. The distribution of the microorganisms between 
the two groups is shown in table 2. No infections with mi-
croorganisms resistant to the study drugs were observed. 
However, in a minority of cases of peritonitis, Enterococcus 
spp. was found in the microbiologic cultures. These organ-
isms have not been clinically interpreted as the responsible 
pathogens since there was no case involving secondary or 
tertiary peritonitis and cure was finally achieved without 
anti-enterococcal medication. Only two patients had posi-
tive blood cultures (blood cultures were performed in all 
patients), but 10% of patients presented signs compatible 
with Systemic Inflammatory Response Syndrome (SIRS) 
[22].
The mean duration of antibiotic treatment was 8 days 
(range 5–15 days) in the cefepime + metronidazole group 
and 9 days in the imipenem-cilastatin group (standard 
deviation 2.83 vs 2.67, respectively; p = 0.28; 95% CI 
1.517–0.445). The maximum duration of therapy was 
15 days in both treatment arms.
Table 1 
Patients’ demographic characteristics.
Cefepime 
+ metronidazole
Imipenem-cilastatin
Patients (n) 60 61
Age, y (SD) 63 (18) 57 (16)
Gender
 Male, n (%) 33 (45) 27 (45)
 Female, n (%) 27 (44) 34 (56)
APACHE II score
(SD)
 6.15 (4.13)  5.48 (2.9)
Body mass index
(kg/m2)
37.97 35.94
Comorbidities, n (%)
 Gastrointestinal 38 (64) 31 (51)
 Cardiovascular 32 (53) 30 (49)
 Endocrinology 13 (22) 15 (25)
 Neurology  9 (15) 3 (5)
 Urogenital
 disorder
 8 (13) 15 (25)
 Pulmonary  7 (12) 10 (17)
 Hematological
 disorder
 6 (10) 3 (5)
 Skin  3 (5) 4 (7)
 Hepatic  1 (2)  3 (5)
Laboratory results
 White blood 
 cells, G/l (range)
11.8 (3.9–29.8) 13.0 (4.8–22.8)
 Platelets, 
 G/l (range)
250 (57–554) 252 (22–512)
 Creatinine,
 μmol/l (range)
91 (51–401) 85 (8–178)
Clinical findings at day 1
 Fever, °C (range) 37.4 (35.7–39.1) 37.3 (35.4–39.0)
 Pulse rate, /min 
 (range)
86 (60–140) 85 (50–130)
 Arterial blood
 pressure, mmHg
130/78 133/76
 Respiratory 
 rate, /m (range)
20 (12–36) 22 (12–48)
All results for age, APACHE II score, laboratory results, hematological 
and blood chemistry values show no significant difference between 
the two treatment groups (tested with Mann-Whitney tests, t-test, or 
Fisher’s exact tests)
n = number; SD = standard deviation
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Among the study population, clinical cure was ob-
tained in 87% of the cefepime + metronidazole group and 
73% of the imipenem-cilastatin group (non-inferiority 
test δ = – 0.1, p < 0.001; 95% CI 0.066–0.2913). A subse-
quent step-down superiority test resulted in a significant 
difference for the treatments (p = 0.004). The primary 
reason for treatment failure was worsening of symptoms 
or the appearance of new symptoms associated with the 
original infection. Of these, eight cases occurred in the ce-
fepime + metronidazole arm vs 16 in the imipenem-cilas-
tatin arm. In the latter group, one case was an early death 
and one case was an inadequate clinical diagnosis. Analysis 
revealed a similar APACHE II score in both groups and 
it was not considered as a significant independent predic-
tor of treatment failure. A logistic regression model was 
used to investigate the association of prognostic factors 
with the likelihood of the response. The stepwise method 
applied to retain the most contributing factors showed a 
significant difference in the final model (p = 0.004, Chi-
square = 15.181). Treatment was a significant parameter 
(odds ratio (OR) = 4.79 and 95% CI for OR, 1.51–15.22). 
In addition, dichotomized APACHE II scores [14] (< 3 
and ≥ 3) and the peak body temperature were found to be 
valuable prediction factors (APACHE II scores: p = 0.041, 
OR 0.267; 95% CI 0.077–0.922; peak body temperature: 
p = 0.047, OR 0.994; 95% CI 0.262–1.010). An APACHE 
II score equal or higher than 3 changed the odds for 
becoming a responder by a factor of 0.267; thus indicating 
that a patient with an APACHE II score less than 3 is more 
likely to become a responder.
Bacteriological eradication rates were 71.6% for the 
cefepime + metronidazole arm and 62.3% in the imipenem-
cilastatin arm (non-inferiority test, δ = 0.01, p = 0.032; 95% 
CI –0.0827–0.1955). The mean time to eradication was 9 days 
in both study groups. Susceptibility profiles of the aerobic 
bacteria isolated from patients in each treatment group were 
similar; no in vitro resistance to either cefepime or imipe-
nem-cilastatin was observed, and susceptibility profiles for 
anaerobic bacteria were sensitive to metronidazole. These 
susceptibility results are in accordance with the microbio-
logic epidemiologic data in the institution. Less than 2% of 
patients presented a surgical wound infection at the end of 
the study which is in accordance with the low rate (< 2%) of 
wound infections observed in our institution.
Both drug regimens were well tolerated. Safety data 
are described for cefepime + metronidazole and for imipe-
nem-cilastatin (Table 3) A total of 29 patients had at least 
one adverse event; 15 in the cefepime + metronidazole arm 
and 14 in the imipenem-cilastatin arm. As shown in table 3, 
no significant difference was noted between the treatment 
groups with regard to adverse events (Fischer’s exact test: 
p = 0.834). Among the most frequent adverse events were 
metabolic and nutritional disorders, gastrointestinal system 
disorders, and liver and biliary disorders (Table 4). In all 
cases, the adverse event was not interpreted as being a side-
effect directly related to the study medication. One patient 
died at the 30-day follow-up period in each study group. 
The deaths were not related to the study drugs adverse 
events but to the patients’ underlying diseases (1 cardio-
vascular and 1 respiratory disease).
Discussion
This study focused on intra-abdominal infections for which 
an operative procedure or a systemic antibiotic treatment 
was required. The demographic profile of the patients was 
representative of the population at risk for these infections. 
Randomization resulted in comparable distribution of the 
patients’ demographic characteristics, although more men 
than women were enrolled in the cefepime + metronida-
zole arm.
In the present study, there was no trend toward more 
severe illness as evidenced by the APACHE II scores of the 
two study groups and as observed in other series [23–25]. This 
may be due to the low APACHE II scores in our study.
Patients with a large variety of abdominal diseases were 
enrolled. The diagnosis was confirmed by surgery or if sur-
gery was not performed, a CT scan confirmed the diagnosis. 
Infections originating from the appendix occurred in 12% of 
all surgical patients. The causal factor was primarily an inflam-
matory process, but 53% of patients entered the study due to 
peritonitis for which a surgical procedure was necessary.
Aerobic organisms were isolated in 31% of cases with 
Escherichia coli being the most frequently isolated.
The local epidemiology during the study period showed 
that Pseudomonas aeruginosa had an MIC90 of 3.5 mcg/ml 
Table 2 
Type of infection and microbiology.
Cefepime
 + metronidazole 
Imipenem-
cilastatin
Type of infection (%) 
Diffuse peritonitis 21 (52) 23 (54)
Diverticulitis 12 (31) 12 (29)
Appendicitis  5 (12)  5 (13)
Perforated ulcer  1 (2)  1 (1)
Cholecystitis  2 (3)  2 (3)
Microbiology (%)
Bacteroides fragilis 10 (24) 15 (25)
Escherichia coli  7 (17) 23 (37)
Pseudomonas aeruginosa  6 (14)  4 (6)
Streptococcus alpha hemolyticus  4 (10)  4 (6)
Enterococcus spp.  3 (7)  4 (6)
Bacteroides stercoris  2 (3)   –
Bacteroides uniformis  2 (3)   –
Proteus mirabilis  2 (3)   –
Propionibacterium spp.  2 (3)  4 (6)
Streptococcus spp.  2 (3)
All operated patients had positive cultures (one or more microorgan-
isms)
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for cefepime and 3.9 mcg/ml for imipenem and E. coli 
strains had an MIC90 of 0.05 mcg/ml for cefepime and 
0.1 mcg/ml for imipenem. Similarly, all the strains isolated 
from the patients in the study had the same sensitivity.
In the present study, the isolation rate for Enterococci 
(6%) was comparable between both groups. The role of 
Enterococci as pathogens in intra-abdominal infections remains 
a subject of debate [3, 26, 27]. They are unlikely pathogens in 
healthy patients, but they may be pathogens in elderly patients, 
the critically ill, those undergoing re-operation for surgical 
complications, or immuno-compromised patients [26–28].
In patients with intra-abdominal infections, it has been 
shown that monotherapy with imipenem-cilastatin was as 
efficacious as a combination of imipenem–cilastatin and 
netilmicin [8]. This demonstrates that broad-spectrum an-
tibiotics such as carbapenem might be sufficient and that 
combination with an aminoglycoside does not improve out-
come and can be replaced by less toxic monotherapy.
Cefepime + metronidazole provides efficacious two-
drug antibiotic therapy for complicated intra-abdominal 
infection due to its broad spectrum of activity against 
colonic aerobes, in particular Enterobacteriaceae [29], and 
anaerobic coverage. Cefepime has very good penetration 
into the abdominal cavity, achieving peritoneal fluid levels 
above the MIC90 for Enterobacteriaceae for most dosing 
intervals [30]. Its safety and efficacy have also been demon-
strated in previous studies conducted in patients with mod-
erate to complicated intra-abdominal infections [15–17].
By univariate analysis, the clinical response of the 
patients treated with cefepime + metronidazole was signifi-
cantly higher than those treated with imipenem-cilastatin. 
This difference was unexpected as we had anticipated a 
similar response rate in both treatment arms. The results 
from the logistic regression model indicate that the likeli-
hood for being a responder is higher with cefepime + met-
ronidazole treatment than with imipenem-cilastatin. A pa-
tient with an APACHE II score less than 3 is more likely to 
be a responder and the lower the peak body temperature at 
baseline, the more likely a patient will achieve cure. Bacte-
riological eradication rates were similar to those reported in 
other series [14]. The situation in our institution regarding 
extended spectrum beta-lactamase-producing gram-nega-
tive rods is not a problem due to the very low incidence, 
as is the case for vancomycin-resistant Enterococci which 
is less than 0.5%. Both treatments were well tolerated 
with similar adverse events in each arm. The differences 
between the two study arms in the present study are difficult 
to explain but could be attributed more likely to the antibi-
otic treatment than to the surgical procedures as all proce-
dures were performed by the same group of surgeons.
In the case of peritonitis, surgery to resolve the prob-
lem responsible for the disease remains essential. Under 
some conditions, such as non-perforated diverticulitis, 
non-surgical treatment and percutaneous drainage in the 
cases of abscess have become the gold standard treatment. 
However, for the cases of diffuse peritonitis, surgery and 
appropriate antibiotic treatment are crucial to cure the 
patient.
The present randomized study has limitations for 
its generalizability as it was conducted in a single center 
study with a relatively small sample size. However, further 
studies of antibiotic efficacy in intra-abdominal infection 
are warranted to confirm our results.
In conclusion, our results show that cefepime + metro-
nidazole continues to be a safe and efficacious therapy with 
a beneficial trend when compared to imipenem-cilastatin 
in the treatment of intra-abdominal infections.
Table 4 
Adverse events experience by patients in both study groups.
Adverse event Cefepime
 + metronidazole
Imipenem-
cilastatin
Hypokalemia 5 3
Nausea 2 –
Diarrhoea 1 3
Duodenum biliar fistula 1a –
Sigmoiditis – 2a
Abscess 1a 2a
Liver enzyme increased 3 1a
Sepsis – 2a
Herpes infection – –
Ascites – 1a
Cardiovascular failure 2a –
Periduodenal haematoma 1a –
Mesenteric thrombosis – 1
Atelectasia 1a –
Arrhythmia 1a –
Vaginitis 1 –
Colon cancer – 1a
Headache 1 1
Renal insufficiency 2a –
a Serious adverse event: one patient could experience more than one 
adverse event
Table 3 
Patients with at least one adverse event cross-tabulation.
Patients with at least one 
adverse event
TotalNo Yes N° of 
episodes
Cefepime + metronidazole
Count 45 15 24 60
Expected count 45.6 14.4    – 60.0
Imipenem-cilastatin
Count 47 14 20 61
Expected count 46.4 14.6 61.0 61.0
Total
Count 92 29 44 121
Expected count 92.0 29.0    – 121.0
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